Alginate nanoparticles as a promising adjuvant and vaccine delivery system

Indian Journal of Pharmaceutical Sciences

Volumn 75, Issue 4, 2013, Pages 442-449

  Sarei, F ^a   Dounighi, N ^b   Zolfagharian, H ^b   Khaki, P ^c   Bidhendi, S ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b Department of Human Vaccines and Sera ^*  (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

Author keywords

Alginate; diphtheria toxoid; nanoparticle; vaccine delivery system

Indexed keywords

ALGINIC ACID; CALCIUM CHLORIDE; DIPHTHERIA ANTIBODY; DIPHTHERIA TOXOID; NANOPARTICLE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DIPHTHERIA; DRUG ANTIGENICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; GELATION; GUINEA PIG; HUMORAL IMMUNITY; IMMUNODIFFUSION; IMMUNOGENICITY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INJECTION SITE ERYTHEMA; NANOENCAPSULATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SHEAR STRESS; SUSTAINED DRUG RELEASE; VACCINATION; VISCOSITY; ZETA POTENTIAL;

EID: 84886390031     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.119829     Document Type: Article

References (47)

1. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly (DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991;59:2978-86.
2. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, Rosa AD. Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 2011;10:1053-61.
3. Malyala P, Singh M. Micro/nanoparticle adjuvants: Preparation and formulation with antigens. Methods Mol Biol 2010;626:91-101.
4. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010;9:1095-107.
5. Callender DP, Jayaprakash N, Bell A, Petraitis V, Petraitiene R, Candelario M, et al. Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits. Antimicrob Agents Chemother 1999;43:972-4. (Pubitemid 29165772)
6. Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst 2003;20:103-37. (Pubitemid 37237277)
7. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL, Alonso MJ. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 2004;17:174-85. (Pubitemid 38955679)
8. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005;22:419-64.
9. Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly (amino acid) derivatives. Biomaterials 2007;28:3427-36. (Pubitemid 46729729)
10. Raghuvanshi RJ, Mistra A, Talwar GP, Levy RJ, Labhasetwar V. Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J Microencapsul 2001;18:723-32. (Pubitemid 32998321)
11. Sajadi Tabassi SA, Tafaghodi M, Jaafari MR. Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 2008;360:12-7.
12. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-9. (Pubitemid 24259861)
13. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila Jato JL, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004;57:123-31. (Pubitemid 38058811)
14. Sharma S, Mukkur TK, Benson HA, Chen Y, Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles. J Pharm Sci 2012;101:233-44.
15. Li X, Kong X, Shi S, Zheng X, Guo G, Wei Y, et al. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol 2008;8;89-99.
16. Gonzalez Ferreiro M, Tillman L, Hardee G, Bodmeier R. Characterization of alginate/poly-L-lysine particles as antisense oligonucleotide carriers. Int J Pharm 2002;239:47-59. (Pubitemid 34615794)
17. Ghiasi Z, Sajadi Tabasi A, Tafaghodi M. Preparation and in vitro characterization of alginate microspheres encapsulated with Autoclaved Leishmania major (ALM) and CpG-ODN. Iran J Basic Med Sci 2007;10:90-8.
18. Jiang G, Min SH, Kim MN, Lee DC, Lim MJ, Yeom YI. Alginate/PEI/DNA polyplexes: A new gene delivery system. Yao Xue Xue Bao 2006;41:439-45. (Pubitemid 44022669)
19. Chretien C, Chaumeil JC. Release of a macromolecular drug from alginate-impregnated microspheres. Int J Pharm 2005;304:18-28. (Pubitemid 41427646)
20. Draget KI, Tylor C. Chemical, physical and biological properties of alginates and their biomedical implications. Food Hydrocoll 2011;25:251-6.
21. Downs EC, Robertson NE, Riss TL, Plunkett ML. Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. J Cell Physiol 1992;152:422-9.
22. Fundueanu G, Nastruzzi C, Carpov A, Desbrieres J, Rinaudo M. Physico-chemical characterization of Ca-alginate microparticles produced with different methods. Biomaterials 1999;20:1427-35. (Pubitemid 29326814)
23. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989;41:809-12. (Pubitemid 20112141)
24. Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008;69:405-16.
25. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Alonso MJ. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: Effect of chitosan pegylation degree. J Control Release 2006;111:299-308.
26. Qurrat ul A, Sharma S, Khuller GK, Garg SK, Alginate-based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003;51:931-8. (Pubitemid 36503426)
27. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int J Pharm 2004;275:13-7. (Pubitemid 38481516)
28. Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol 2008;8:1773-80.
29. Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv 2004;1:195-201.
30. Machado AH, Lundberg D, Ribeiro AJ, Veiga FJ, Lindman B, Miguel MG, et al. Preparation of calcium alginate nanoparticles using water-in-oil (W/O) nanoemulsions. Langmuir 2012;28:4131-41.
31. Fang Y, Al-Assaf S, Phillips GO, Nishinari K, Funami T, Williams PA, et al. Multiple steps and critical behaviors of the binding of calcium to alginate. J Phys Chem B 2007;111:2456-62. (Pubitemid 46548726)
32. Moloney PJ, Beecher Weld C. Diphtheria toxin-antitoxin flocculation (Ramon test). J Pathol 1925;28:655-72.
33. Ma T, Zuazaga G. Micro-Kjeldahl determination of nitrogen. A new indicator and an improved rapid method. Ind Eng Chem Anal Ed 1942;14:280-2.
34. Rajaonarivony M, Vauthier C, Couarraze G, Puisieux F, Couvreur P. Development of a new drug carrier made from alginate. J Pharm Sci 1993;82:912-7. (Pubitemid 23317253)
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
36. Sarmento B, Ferreira D, Veiga F, Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym 2006;66:1-7. (Pubitemid 44376662)
37. Kindt TJ, Goldsby RA, Osborne BA, Kuby J. Kuby immunology. New York: W.H. Freeman; 2007.
38. Amidi M, Pellikaan HC, Hirschberg H, de Boer AH, Crommelin DJ, Hennink WE, et al. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: Preparation, characterization and evaluation in guinea pigs. Vaccine 2007;25:6818-29. (Pubitemid 47332722)
39. World Health organization. Requirements for DTP. World Health Organ Tech Rep Ser 1990;800:87-179.
40. Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 1987;3:233-61. (Pubitemid 17021225)
41. Ma X, Vacek I, Sun A. Generation of alginate-poly-l-lysine-alginate (APA) biomicrocapsules: The relationship between the membrane strength and the reaction conditions. Artif Cells Blood Substit Immobil Biotechnol 1994;22:43-69. (Pubitemid 24204443)
42. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: Formulation development, pharmacokinetics and therapeutic potentia. Indian J Chest Dis Allied Sci 2006;48:171-6.
43. Anal AK, Bhopatkar D, Tokura S, Tamura H, Stevens WF. Chitosan-alginate multilayer beads for gastric passage and controlled intestinal release of protein. Drug Dev Ind Pharm 2003;29:713-24. (Pubitemid 36835163)
44. Coppi G, Iannuccelli V, Leo E, Bernabei MT, Cameroni R. Chitosan-alginate microparticles as a protein carrier. Drug Dev Ind Pharm 2001;27:393-400. (Pubitemid 32612728)
45. Kahl LP, Lelchuk R, Scott CA, Beesley J. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis. Infect Immun 1990;58:3233-41. (Pubitemid 20293430)
46. Bowersock TL, HogenEsch H, Suckow M, Guimond P, Martin S, Borie D, et al. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999;17:1804-11. (Pubitemid 29138921)
47. Tafaghodi M, Sajadi Tabassi SA, Jaafari MR. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 2006;319:37-43 (Pubitemid 44051800)